IMNN — Imunon, Inc.

Is IMNN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Imunon, Inc. (IMNN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.59. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Imunon, Inc. shows the typical profile of a small, high‑volatility biotech: limited public financial disclosure, dependency on binary clinical/regulatory events and high financing risk. Current market flows favor large‑cap pharma and defensive healthcare, reducing near‑term investor appetite for microcap risk without clear catalysts. Absent forthcoming positive clinical updates, partnerships or demonstrable revenue paths, the outlook is uncertain and driven primarily by company‑specific news and capital‑markets dynamics.

Key factors

  • Limited public financial disclosure and EDGAR data available, creating uncertainty about cash runway and revenue visibility
  • Micro-/small‑cap biotech profile with high sensitivity to binary clinical or regulatory news and financing events
  • Broader market tone is cautiously optimistic for healthcare, but flows favor large‑cap pharma and defensive names rather than speculative microcaps
  • Potential near‑term catalysts from company announcements, trial readouts or partnership/licensing activity that could move the stock materially
  • Sector dynamics (convertible-debt/dilution pressure across biotech) increase likelihood of financing-driven share overhang
  • Low liquidity and retail-driven volatility could amplify price moves around news

Risks

  • Insufficient cash runway leading to dilutive financing or pressured convertible issuance
  • Clinical trial failure or negative regulatory feedback for any pipeline assets
  • Extreme share price volatility and low trading volume, making execution and exits difficult
  • Competition from better‑funded biopharma companies or established therapeutics with deeper commercialization channels
  • Adverse macro or sector rotations that favor large‑cap defensive healthcare and reduce risk appetite for microcaps
  • Lack of clear analyst coverage and sparse social/research signal increasing information asymmetry

See today's live rating, score and targets

Members see the live hourly rating for IMNN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.